Allergy Therapeutics (GB:AGY) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Allergy Therapeutics has reported successful dose escalation in its Phase I/IIa VLP Peanut PROTECT trial, with no safety concerns at higher doses for both peanut allergic patients and healthy subjects. The company is set to continue with further dose increases and is anticipating preliminary efficacy results by the end of 2024, as it seeks to address the high unmet need in peanut allergy treatment.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
